Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Studied

A randomized phase 2 trial tested daily subcutaneous liraglutide versus placebo for non-alcoholic steatohepatitis over the treatment period.

Who / model

Adults with overweight and clinical NASH were randomized to liraglutide or placebo; end-of-treatment biopsies were available for participants in both groups.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

NASH resolution was more common with liraglutide than placebo, while fibrosis progression was less common. Gastrointestinal events were frequent in both groups.

Limits

The biopsy analysis included fewer participants than the randomized groups, and the authors called for longer studies.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary